StreetInsider.com News Articles

Form 8-K CUMBERLAND PHARMACEUTICA For: Oct 23

Fri, 23 Oct 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20261023/27228540.html

Cumberland Pharmaceuticals reports Phase 2a ifetroban trial results

Fri, 23 Oct 2026 16:06:13 -0400

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc), a rare autoimmune disease affecting approximately 100,000 people in the U.S.

The 12-month pilot trial enrolled 41 subjects, with 31 receiving ifetroban and 10 receiving a placebo. Patients had either diffuse cutaneous SSc or SSc-associated pulmonary arterial hypertension. The trial's primary objective was to evaluate safety, not efficacy.

Ifetroban was generally well tolerated. Gastrointestinal adverse events occurred more frequently in the ifetroban group than in the placebo group, though most were mild and resolved. A modest increase in bleeding-related

Cumberland Pharmaceuticals reports Phase 2a ifetroban trial results

Fri, 23 Oct 2026 16:06:13 -0400

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Fri, 23 Oct 2026 16:05:00 -0400

Ifetroban was well tolerated in patients with systemic sclerosis

NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis ("SSc"). These results support the safety and tolerability

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Fri, 23 Oct 2026 16:05:00 -0400

Ifetroban was well tolerated in patients with systemic sclerosis

CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

Fri, 23 Oct 2026 09:05:00 -0400

NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

A national webcasting event and conference call will

CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

Fri, 23 Oct 2026 09:05:00 -0400

A national webcasting event and conference call will

CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM

Mon, 19 Oct 2026 16:05:00 -0400

NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

A national webcasting event and conference call

CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM

Mon, 19 Oct 2026 16:05:00 -0400

A national webcasting event and conference call

Form 8-K/A CUMBERLAND PHARMACEUTICA For: Apr 21

Fri, 11 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260911/27053476.html

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 28

Fri, 28 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260828/26999003.html

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 28

Fri, 28 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260828/26999003.html

Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892172.html

Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892172.html

Cumberland Pharmaceuticals (CPIX) Reports Q2 Loss of $0.20

Tue, 04 Aug 2026 17:57:28 -0400

Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q2 EPS of ($0.20). Revenue for the quarter came in at $166.45 million.

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 04

Tue, 04 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260804/26868042.html

Form 8-K CUMBERLAND PHARMACEUTICA For: Aug 04

Tue, 04 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260804/26868042.html

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.

During the second quarter, Cumberland completed a transaction with Apotex Health, the largest Canadian pharmaceutical company, to integrate their branded business. Under the terms of the agreement, Apotex acquired Cumberland's portfolio of FDA-approved brands

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Tue, 04 Aug 2026 17:06:00 -0400

$100 million Strategic Transaction Closed

Special Shareholder Dividend Funded

Advancing Late Stage Clinical Pipeline